JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Начало・Списък с акции・Clearside Biomedical Inc

Clearside Biomedical Inc

Затворен

0.38 -2.56

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.38

Максимум

0.4

Ключови измерители
By Trading Economics
Приходи	-917K -8.2M
Продажби	2M 2.3M
Марж на печалбата	-352.918
Служители	32
EBITDA	-102K -4.8M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+357.5% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-37M 32M
Предишно отваряне	2.94
Предишно затваряне	0.38

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

0.8417 / 0.8939 Подкрепа & съпротива

Clearside Biomedical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.08.2025 г., 17:49 ч. UTC

Значими двигатели на пазара

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11.08.2025 г., 17:18 ч. UTC

Значими двигатели на пазара

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11.08.2025 г., 16:25 ч. UTC

Печалби

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11.08.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

11.08.2025 г., 23:42 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

11.08.2025 г., 23:42 ч. UTC

Пазарно говорене

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11.08.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11.08.2025 г., 23:32 ч. UTC

Пазарно говорене

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11.08.2025 г., 23:02 ч. UTC

Пазарно говорене

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

11.08.2025 г., 20:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11.08.2025 г., 20:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bakkt Holdings 2Q Rev $577.9M >BKKT

11.08.2025 г., 20:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement 2Q Rev $25.8M >EXOD

11.08.2025 г., 20:14 ч. UTC

Пазарно говорене

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11.08.2025 г., 19:12 ч. UTC

Пазарно говорене

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11.08.2025 г., 18:56 ч. UTC

Пазарно говорене

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11.08.2025 г., 18:31 ч. UTC

Пазарно говорене

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11.08.2025 г., 17:43 ч. UTC

Пазарно говорене

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11.08.2025 г., 17:28 ч. UTC

Пазарно говорене

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11.08.2025 г., 17:16 ч. UTC

Пазарно говорене

Commodity Longs Fall to 11-Month Low -- Market Talk

11.08.2025 г., 16:42 ч. UTC

Придобивния, сливания и поглъщания

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11.08.2025 г., 16:27 ч. UTC

Придобивния, сливания и поглъщания

BBVA Says Sabadell Offer Remains in Effect

11.08.2025 г., 16:26 ч. UTC

Придобивния, сливания и поглъщания

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11.08.2025 г., 16:25 ч. UTC

Придобивния, сливания и поглъщания

Banco de Sabadell Announced TSB Sale on July 1

11.08.2025 г., 16:25 ч. UTC

Придобивния, сливания и поглъщания

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Сравнение с други в отрасъла

Ценова промяна

Clearside Biomedical Inc Прогноза

Ценова цел

By TipRanks

357.5% нагоре

12-месечна прогноза

Среден 1.83 USD 357.5%

Висок 3 USD

Нисък 0.5 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Clearside Biomedical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Clearside Biomedical Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.8417 / 0.8939Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.